Cancer reports最新文献

{"title":"OncoTrace-TOO: Interpretable Machine Learning Framework for Cancer Tissue-of-Origin Identification Using Transcriptomic Signatures","authors":"Yang Hao,&nbsp;Haochun Huang,&nbsp;Daiyun Huang,&nbsp;Jianwen Ruan,&nbsp;Xin Liu,&nbsp;Jianquan Zhang","doi":"10.1002/cnr2.70311","DOIUrl":"https://doi.org/10.1002/cnr2.70311","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer of unknown primary remains a formidable diagnostic challenge due to the inability to pinpoint the primary tumor site, which restricts the use of targeted therapeutics. Although machine-learning methods that integrate transcriptomic approaches have provided valuable insights into tumor origins, they often face challenges in distinguishing biologically similar tumors and typically lack biological interpretability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aims to develop a transparent and biologically interpretable machine learning framework to accurately classify tissue-of-origin across diverse cancer types, thereby facilitation clinical diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We designed OncoTrace-TOO, a novel tissue-of-origin classification model based on gene expression profiles. The model utilizes pan-cancer discriminative molecular features identified through one-vs-rest differential expression analysis and applies logistic regression as the classification algorithm.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>OncoTrace-TOO achieved an overall accuracy of 0.967, with perfect classification for seven cancer types (e.g., CHOL, DLBC, and LAML). The model demonstrated high predictive accuracy in both primary and metastatic cancers across TCGA and GEO validation datasets, with enhanced capability in resolving histologically related malignancies as well as classifying rare cancer subtypes. When applied to independent clinical tumor samples, the model achieved TOO prediction accuracies of 0.857, further validating its robustness. Importantly, the framework offers biologically interpretable predictions by revealing tumor-specific molecular signatures, thus enhancing its clinical applicability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>OncoTrace-TOO not only offers high predictive accuracy for tissue-of-origin classification, but also delivers biologically meaningful insights that support clinical decision-making. This framework holds promise for improving diagnostic precision and guiding personalized treatment in challenging cancer cases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70311","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population-Based Survival Analysis of Solitary Plasmacytoma of Spine in the United States From 2000 to 2020","authors":"Kevin E. Agner,&nbsp;Luke G. Comisford,&nbsp;Alec G. Kotler,&nbsp;Jacob A. Wells,&nbsp;Michael C. Larkins","doi":"10.1002/cnr2.70299","DOIUrl":"https://doi.org/10.1002/cnr2.70299","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Solitary plasmacytomas of bone of the spine (SPBS) are rare tumors associated with significant morbidity and mortality, especially with progression to multiple myeloma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>While demographic and treatment factors influencing survival have been investigated in previous studies, analysis using the most recent population data and assessing more granular data such as the extent of surgical resection in conjunction with radiotherapy has yet to be performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Surveillance, Epidemiology, and End Results (SEER) Program was queried for patients with a diagnosis of SPBS (ICD-0-3 code 9731/3). Demographic and treatment variables were analyzed using Cox regression, and a log-rank analysis was used to assess 5-year overall survival (5y OS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1391 patients diagnosed with localized SPBS were identified. Multivariate analysis revealed that increasing age at diagnosis (HR = 2.25, <i>p</i> &lt; 0.001) and higher income (HR = 1.471; <i>p</i> &lt; 0.001) were significantly associated with decreased 5y OS, while being married was associated with improved survival (HR = 0.671, <i>p</i> &lt; 0.001). Furthermore, treatment with radiation therapy (HR = 0.613, <i>p</i> &lt; 0.001) and gross total resection (HR = 0.657; <i>p</i> = 0.020) were associated with improved survival outcomes. Univariate analysis confirmed the demographic factor significance, with radiotherapy combined with surgery being associated with improved survival versus sole radiotherapy (49.4% vs. 40.8%; <i>p</i> = 0.004).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This population-based analysis of SPBS highlights key prognostic factors for 5y OS. Increased age, higher income, and single marital status were associated with worse outcomes, while radiation therapy and greater extent of surgical procedure improved survival. Notably, radiotherapy combined with surgery showed better survival than radiation alone, challenging current national guidelines that recommend radiotherapy with or without surgery. Additionally, gross total resection demonstrated the highest overall survival among the various surgical procedures. These findings suggest that incorporating combined therapy into treatment protocols could improve outcomes and refine future guidelines.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70299","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study","authors":"Junya Arima,&nbsp;Hirofumi Yoshino,&nbsp;Shuichi Tatarano,&nbsp;Akihiko Mitsuke,&nbsp;Yoichi Osako,&nbsp;Takashi Sakaguchi,&nbsp;Ryosuke Matsushita,&nbsp;Satoru Inoguchi,&nbsp;Yasutoshi Yamada,&nbsp;Hideki Enokida","doi":"10.1002/cnr2.70308","DOIUrl":"https://doi.org/10.1002/cnr2.70308","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Combining the probiotic product CBM588 with immune checkpoint inhibitors (ICIs) has shown improved prognosis in several cancers. Pembrolizumab alone as a second-line treatment for urothelial cancer (UC) extends prognosis by only 3 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This is a retrospective study that examined the effects of CBM588 combined with pembrolizumab in advanced UC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The study included 44 patients who had recurrence or progression after first-line chemotherapy with cisplatin or carboplatin. The study compared 33 patients treated with pembrolizumab alone and 11 patients treated with CBM588 plus pembrolizumab over a median observation period of 12 months. The combination of CBM588 and pembrolizumab significantly improved progression-free survival (PFS; <i>p</i> = 0.004) and overall survival (OS; <i>p</i> = 0.02). Multivariate analysis identified CBM588 as a significant prognostic factor for both PFS (hazard ratio: 0.074, <i>p</i> = 0.0008) and OS (hazard ratio: 0.105, <i>p</i> = 0.0056).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These results suggest the effectiveness of the CBM588 combination with ICI treatment in UC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70308","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and Clinicopathological Significance of CD47 in Human Solid Tumors: An Updated Systematic Reviews and Meta-Analysis","authors":"Yongzhi Ye,&nbsp;Meiqiong Chen,&nbsp;Fada Ji,&nbsp;Suicai Mi,&nbsp;Zhixiong Chen,&nbsp;Xiaowei Wu,&nbsp;Qiurong He,&nbsp;Xiaodong Liu","doi":"10.1002/cnr2.70296","DOIUrl":"https://doi.org/10.1002/cnr2.70296","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>High expression levels of cluster of differentiation 47 (CD47) have been recognized as poor survival in several different cancers. Nevertheless, the significance of CD47 in patients with solid tumors remains controversial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The objective of this study is to elucidate whether elevated CD47 expression independently predicts a poor prognosis across solid tumors through pooled survival and clinicopathological analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This meta-analysis was based on a search of PubMed, Embase, and Web of Science databases to obtain 20 eligible published studies (totaling 4019 patients) between January 2018 and January 2024. The combined hazard ratios (HRs) for overall survival (OS) were evaluated, and the HRs for relapse-free survival (RFS), progression-free survival (PFS), and disease-free survival (DFS), as well as odds ratios for clinicopathological data, were also respectively combined. The data obtained from these studies were extracted from these published studies and analyzed. This study suggested that CD47 overexpression was related to shorter OS times in human solid tumors, with a combined HR for OS (according to the univariate analysis) of HR = 1.63 (95% confidence intervals,[ 95% CIs]: 1.45–1.83; <i>p</i> &lt; 0.00001), and a pooled HR for OS (according to the multivariate analysis) of HR = 2.02 (95% CI: 1.43–2.84; <i>p</i> &lt; 0.0001). The subgroup analysis revealed that CD47 overexpression was related to inferior OS rates according to country, cancer type, sample size, analysis type, and the method via which the HR value was obtained (i.e., reported or extracted; <i>p</i> &lt; 0.05); in addition, a high expression level of CD47 was also a predictor of poor DFS, PFS, and RFS rates (<i>p</i> &lt; 0.00001). Certain factors, such as age (≥ 60 years old), lymph node metastasis, TNM staging, differentiation type, and tumor recurrence, resulted in an upregulation of CD47 (<i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This meta-analysis indicates that CD47 overexpression is significantly associated with poor clinical outcomes, advanced clinical stages, and poor differentiation in solid tumor patients, particularly, in cases involving tumors in the digestive and respiratory systems. These findings suggest that CD47 could serve as a valuable prognostic biomarker and therapeutic target.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70296","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic Low-Grade Glioma Successfully Treated in a Pediatric Patient With BRAF A598_T599insI Mutation","authors":"Pierluigi Calò,&nbsp;Safiatou Diallo,&nbsp;Laetitia Lebrun,&nbsp;Nathalie Gilis,&nbsp;Marco Preziosi,&nbsp;Pierre Leblond","doi":"10.1002/cnr2.70309","DOIUrl":"https://doi.org/10.1002/cnr2.70309","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pediatric low-grade gliomas are common brain tumors often driven by MAPK pathway alterations, including rare BRAF mutations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>This case report describes the first use of treatment combining dabrafenib and trametinib in a 10-year-old boy with pleomorphic xanthoastrocytoma harboring a BRAF A598_T599insI mutation. Surgery and chemotherapy failed, leading to metastatic progression; yet targeted therapy has achieved a sustained clinical and radiological response, lasting more than 2 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case highlights the potential of RAF/MEK inhibitors in rare BRAF-mutated tumors and underscores the need for research to optimize treatment duration, manage side effects, and explore their role in non-canonical mutations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70309","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applying Parse's Theory in Caring for a Depressed Patient Following Hysterectomy With Oophorectomy: A Case Study","authors":"Arian Mobasheri,&nbsp;Azar Darvishpour","doi":"10.1002/cnr2.70301","DOIUrl":"https://doi.org/10.1002/cnr2.70301","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Depression is a common complication in women undergoing hysterectomy. By utilizing nursing theories in patient care, improved care standards, more affordable care costs, and greater quality of life can be achieved. Parse's theory of human becoming is among the nursing theories prioritizing each individual's conception of quality of life as a crucial nursing goal. This study aimed to apply Parse's theory of human becoming to the care of a depressed patient following a hysterectomy with oophorectomy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>The participant was a 44-year-old woman who underwent hysterectomy with bilateral oophorectomy on January 1, 2023, following a diagnosis of grade 1 right ovarian cancer. After three days of hospitalization, she returned home to live with her husband and four children. Postoperative care was provided by a home care nurse—also the researcher—who observed signs of emotional distress and depressive symptoms, including social withdrawal, irritability, and loss of interest in daily activities. The nurse implemented nursing interventions grounded in Parse's Human Becoming Theory, including therapeutic communication, mindfulness practices, journaling, and involving the family in emotional support. Data were analyzed using Parse's qualitative research methodology (2011).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Based on the first principle of Parse's theory (meaning), the findings showed that patients' meaning and values of life changed from “disappointment” to “hope.” In the second principle (rhythmic patterns), contradictory patterns of “dependency-nondependency” and “hope-disappointment” were identified. Based on the third principle (transcendence), with the actual presence of a nurse and the implementation of care and treatment, the patient's mental state switched from “depression and despair” to “hope and happiness.” This research found that Parse's theory of nursing was effective in alleviating depression in patients following hysterectomy with oophorectomy surgery. This study also highlights the importance of utilizing nursing theories in patient care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70301","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the mTOR Signaling Pathway Through miR-100 and miR-101 in De Novo Acute Myeloid Leukemia: Implications for Therapeutic Intervention","authors":"Maryam Kargar,&nbsp;Mehdi Allahbakhshian Farsani,&nbsp;Javad Garavand,&nbsp;Mahnaz Gorji,&nbsp;Mohammad Rafiee,&nbsp;Seyed Sobhan Bahreiny,&nbsp;Mohammad Hossein Mohammadi","doi":"10.1002/cnr2.70264","DOIUrl":"https://doi.org/10.1002/cnr2.70264","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Microribonucleic acid (MicroRNAs/miRNAs) play a significant role in cancer progression by changing cellular functions through the modulation of protein expressions. The potential of different miRNAs to alter the expression of the mammalian target of rapamycin (<i>mTOR</i>)/protein kinase B (<i>PKB</i> or <i>AKT</i>)/phosphatidylinositol-3-kinase (<i>PI3K</i>) signaling cascade, a key pathway in the progression of acute myeloid leukemia (AML), has been demonstrated across different types of cancers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aims to explore the effects of <i>miR-100</i> and <i>miR-101</i> on the <i>mTOR/AKT/PI3K</i> signaling pathway in AML.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Initially, we employed the TargetScan, miRDB, and miRanda databases to identify the target proteins of <i>miR-100</i> and <i>miR-101</i>. Following a comprehensive analysis, we identified the <i>mTOR</i>/<i>AKT</i>/<i>PI3K</i> signaling pathway as a significant target for investigation in patients with AML. In this case–control study, the expression levels of miRNAs and genes were analyzed in 21 AML patients and 9 healthy controls using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The results showed that <i>miR-100</i> was significantly upregulated, while <i>miR-101</i>, <i>mTOR</i>, and <i>PI3K</i> were downregulated in AML patients. Correlation analysis revealed a negative relationship for <i>miR-100</i> and a positive one for <i>miR-101</i> with <i>mTOR</i>, but no significant correlation with <i>AKT1</i> and <i>PI3K</i> genes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings suggest that both <i>miR-100</i> and <i>miR-101</i> act as tumor suppressors via the <i>mTOR/AKT/PI3K</i> signaling pathway, highlighting their potential as therapeutic targets in AML.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70264","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144767262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Cholinesterase Is a Potential Poor Prognostic Factor in Colorectal Cancer Presenting With Tumor Markers Negative","authors":"Tawfik Ali Hamood Alburiahi,&nbsp;Lei Liang,&nbsp;Weiqing Liu,&nbsp;Zhiyong Kou,&nbsp;Yunfei Zhang,&nbsp;Ning Xu,&nbsp;Jun Yang","doi":"10.1002/cnr2.70266","DOIUrl":"https://doi.org/10.1002/cnr2.70266","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Colorectal cancer (CRC) is the third most common malignant tumor in the world and has the second highest mortality rate. Tumor markers are proteins used to diagnose and monitor cancer. Serum cholinesterase (CHE) is a nutritional indicator indicating the liver''s ability to synthesize proteins and is a predictor of CRC. Butyrylcholinesterase (BCHE), a CHE enzyme encoded by the BCHE gene, is synthesized by the liver and released into the serum.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To study the association between CHE and survival prognosis in CRC with tumor markers negative (TMN). The relationship between the BCHE gene and immune cell infiltration was also explored.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The clinical data of patients with CRC were collected. The data included tumor markers and biochemical indicators. Patients were divided into different groups for prognosis analysis. CHE levels were used as the cutoff for classification. Further analysis was conducted on the all-TMN group. CHE was found to be correlated with survival prognosis. This study also analyzed BCHE gene expression in cancer and normal tissues. A correlation analysis was conducted with other factors.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;(1) Among 1140 patients who met the criteria, the TMN group (&lt;i&gt;n&lt;/i&gt; = 369) had a higher survival rate (89.7%) than the TMP group (&lt;i&gt;n&lt;/i&gt; = 771, 83.3%; &lt;i&gt;p&lt;/i&gt; = 0.035). (2) Among 1140 CHE, the low cholinesterase (CHE&lt;sup&gt;Low&lt;/sup&gt;) group (&lt;i&gt;n&lt;/i&gt; = 165) had worse survival (73.9%) compared to the high cholinesterase (CHE&lt;sup&gt;High&lt;/sup&gt;) group (&lt;i&gt;n&lt;/i&gt; = 975, 87.3%; &lt;i&gt;p&lt;/i&gt; &lt; 0.001). (3) In the TMN group, CHE&lt;sup&gt;Low&lt;/sup&gt; (&lt;i&gt;n&lt;/i&gt; = 48) had worse survival (79.2%) than CHE&lt;sup&gt;High&lt;/sup&gt; (&lt;i&gt;n&lt;/i&gt; = 321, 91.3%; &lt;i&gt;p&lt;/i&gt; = 0.008). Similarly, in the TMP group, CHE&lt;sup&gt;Low&lt;/sup&gt; (&lt;i&gt;n&lt;/i&gt; = 117) showed poorer survival (71.8%) compared to CHE&lt;sup&gt;High&lt;/sup&gt; (&lt;i&gt;n&lt;/i&gt; = 654, 85.3%; &lt;i&gt;p&lt;/i&gt; &lt; 0.001). (4) In colorectal cancer with all TMN, CHE ≤ 5.4 U/L, BMI &lt; 18.5 kg/m&lt;sup&gt;2&lt;/sup&gt;, and pN2 were independent detrimental prognostic factors for overall survival (OS) (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). (5) BCHE expression differs between cancer and normal CRC tissues. BCHE expression correlated with pathological stage and progression-free survival. BCHE expression positively correlated with immune cell infiltration (&lt;i&gt;p&lt;/i&gt; = 2.7e&lt;sup&gt;−28&lt;/sup&gt;, &lt;i&gt;r&lt;/i&gt; = 0.59), distinctively M2 macrophage infiltration (&lt;i&gt;p&lt;/i&gt; &lt; 0.0001).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;se","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70266","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144758468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Advanced Lung Adenocarcinoma Successfully Treated by Intratumoral Injection of Tirelizumab Under Tracheoscopy.","authors":"Huiying Liu, Xuemao Liu, Wen Jiang, Bin Yin, Dongmei Wang, Xiaoping Yang, Wenqing Jiang","doi":"10.1002/cnr2.70279","DOIUrl":"10.1002/cnr2.70279","url":null,"abstract":"<p><strong>Introduction: </strong>Lung cancer is a leading cause of cancer-related deaths, with an annual mortality rate of nearly 1.8 million. Among its subtypes, lung adenocarcinoma is increasingly prevalent. Due to its often asymptomatic nature, most patients are diagnosed at advanced stages, missing the optimal window for surgery and resulting in a poor 5-year survival rate.</p><p><strong>Case presentation: </strong>We present the case of an 83-year-old patient with stage IV lung adenocarcinoma treated with four cycles of intravenous Tirelizumab and two cycles of intratumoral Tirelizumab via tracheoscopy. The patient achieved partial clinical remission, with tumor lesions continuing to shrink upon follow-up by August 24, 2024. No treatment-related adverse reactions were observed, and the patient's immune function remained normal.</p><p><strong>Conclusions: </strong>This case suggests that systemic intravenous Tirelizumab combined with tracheoscopic intratumoral injection may offer a safe and effective treatment strategy for lung adenocarcinoma, particularly for patients unsuitable for chemotherapy or surgery. However, further prospective studies and clinical trials are needed to validate these findings.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":"e70279"},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12332419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Lower-Grade Gliomas, the SPARC Family Exacerbates Prognosis by Influencing Immunity, Stemness, and Metabolism.","authors":"Qiaoying Peng, Wenxia Zhou, Ying Chen, Yong Cai","doi":"10.1002/cnr2.70307","DOIUrl":"10.1002/cnr2.70307","url":null,"abstract":"<p><strong>Background: </strong>Involvement of the SPARC stromal protein family in crucial biological regulatory mechanisms is well-documented. But understanding the consequences of imbalanced SPARC protein activity in lower-grade glioma (LGG) is still emerging.</p><p><strong>Aims: </strong>Examining the clinical significance of SPARC proteins, researchers employed RNA-seq data from diverse patient groups to gain insight. A novel SPARCScore was developed via LASSO regression analysis, leveraging data from the PanCanAtlas and MEXPRESS to shed light on the molecular mechanisms involved.</p><p><strong>Methods and results: </strong>Our findings indicate that a majority of SPARC family proteins show atypical expression levels, correlating significantly with adverse outcomes in LGG. Our construction of an SPARCscore, indicative of the SPARC family's presence, revealed a direct correlation between a high SPARCscore and worsened tumor prognosis, irrespective of radiotherapy or chemotherapy treatments. The SPARCScore risk groups showed distinct drivers: PIK3CA predominantly influenced the low-risk category, whereas EGFR was a key factor in the high-risk group. High SPARCScore tumors exhibited a mutation profile similar to glioblastoma, marked by reduced methylation and diverse glioma stem cells (GSC). Conversely, the low SPARCScore tumors were characterized by increased methylation and limited GSC variety. Furthermore, the high-SPARCScore group was notable for its pronounced inflammatory and extracellular matrix signatures, along with activated metabolic pathways. These patterns were closely linked to prognosis.</p><p><strong>Conclusion: </strong>In essence, this research highlights the significance of SPARC proteins in LGG, offering insights into promising avenues for targeted therapy.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":"e70307"},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}